Xiaolong Liu Selected Research

AQ4N

1/2019	Programmable Therapeutic Nanodevices with Circular Amplification of H2 O2 in the Tumor Microenvironment for Synergistic Cancer Therapy.
10/2018	pH/hypoxia programmable triggered cancer photo-chemotherapy based on a semiconducting polymer dot hybridized mesoporous silica framework.
1/2018	Chemotherapeutic Drug Based Metal-Organic Particles for Microvesicle-Mediated Deep Penetration and Programmable pH/NIR/Hypoxia Activated Cancer Photochemotherapy.
1/2017	Smart Cu(II)-aptamer complexes based gold nanoplatform for tumor micro-environment triggered programmable intracellular prodrug release, photodynamic treatment and aggregation induced photothermal therapy of hepatocellular carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiaolong Liu Research Topics

Disease

153	Neoplasms (Cancer) 07/2022 - 01/2010
50	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 06/2014
25	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2014
16	Carcinogenesis 01/2022 - 02/2013
13	Hypoxia (Hypoxemia) 10/2021 - 01/2017
9	Liver Neoplasms (Liver Cancer) 01/2022 - 08/2014
6	Inflammation (Inflammations) 02/2022 - 08/2015
6	Breast Neoplasms (Breast Cancer) 01/2022 - 06/2013
6	Infections 11/2021 - 04/2007
6	Thrombosis (Thrombus) 09/2021 - 11/2014
5	Liver Cirrhosis (Hepatic Cirrhosis) 03/2022 - 12/2017
4	Pain (Aches) 06/2022 - 07/2017
4	Starvation 04/2022 - 01/2017
4	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 08/2017
3	Hepatitis B 08/2021 - 11/2014
3	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 06/2020 - 01/2013
3	Necrosis 01/2020 - 04/2015
3	Urinary Bladder Neoplasms (Bladder Cancer) 01/2020 - 07/2018
3	Type 2 Diabetes Mellitus (MODY) 11/2019 - 05/2011
2	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2022 - 12/2019
2	Bites and Stings (Sting) 01/2022 - 01/2021
2	Sepsis (Septicemia) 11/2021 - 01/2021
2	Lymphatic Metastasis 08/2021 - 01/2019
2	Liver Diseases (Liver Disease) 01/2021 - 01/2020
2	Stomach Neoplasms (Stomach Cancer) 01/2021 - 01/2021
2	Lung Neoplasms (Lung Cancer) 01/2021 - 06/2012
2	Melanoma (Melanoma, Malignant) 01/2021 - 03/2016
2	Carcinoma (Carcinomatosis) 01/2021 - 03/2014
2	Hyperthermia 01/2021 - 09/2019
2	Triple Negative Breast Neoplasms 01/2021 - 01/2013

Drug/Important Bio-Agent (IBA)

28	Biomarkers (Surrogate Marker)IBA 01/2022 - 07/2013
26	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2012
16	Pharmaceutical PreparationsIBA 01/2021 - 01/2015
15	Therapeutic UsesIBA 01/2021 - 09/2017
13	1-phenyl-3,3-dimethyltriazene (PDT)IBA 10/2021 - 04/2015
9	Biological ProductsIBA 01/2022 - 01/2017
9	Messenger RNA (mRNA)IBA 09/2021 - 06/2012
9	MicroRNAs (MicroRNA)IBA 01/2021 - 06/2012
8	AntigensIBA 01/2022 - 04/2007
7	CytokinesIBA 01/2022 - 02/2015
7	Photosensitizing Agents (Photosensitizers)IBA 10/2021 - 04/2015
7	PolymersIBA 04/2020 - 01/2016
6	LipidsIBA 12/2019 - 12/2007
5	AcidsIBA 06/2022 - 01/2017
5	Reactive Oxygen Species (Oxygen Radicals)IBA 02/2022 - 04/2015
5	Small Interfering RNA (siRNA)IBA 01/2021 - 02/2016
5	Silicon Dioxide (Silica)FDA LinkGeneric 01/2021 - 01/2015
4	Glucose (Dextrose)FDA LinkGeneric 04/2022 - 06/2012
4	Oxygen (Dioxygen)IBA 02/2022 - 03/2019
4	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 01/2021
4	AntibodiesIBA 01/2022 - 04/2007
4	IonsIBA 01/2022 - 08/2018
4	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2017
4	EnzymesIBA 10/2021 - 09/2017
4	Long Noncoding RNAIBA 09/2021 - 09/2015
4	Sorafenib (BAY 43-9006)FDA Link 07/2021 - 07/2016
4	Capsules (Microcapsules)IBA 06/2021 - 11/2014
4	Carrier Proteins (Binding Protein)IBA 01/2021 - 07/2016
4	AQ4NIBA 01/2019 - 01/2017
4	polydopamineIBA 05/2016 - 03/2015
3	Glutathione (Reduced Glutathione)IBA 01/2022 - 10/2017
3	GlypicansIBA 01/2022 - 06/2014
3	phytochlorinIBA 07/2021 - 04/2015
3	Immune Checkpoint InhibitorsIBA 06/2021 - 07/2020
3	MetalsIBA 11/2019 - 01/2018
3	ProdrugsIBA 01/2019 - 01/2017
3	Doxorubicin (Adriamycin)FDA LinkGeneric 06/2018 - 01/2015
3	MicellesIBA 10/2017 - 01/2016
3	Ferrosoferric Oxide (Magnetite)FDA Link 01/2017 - 05/2016
2	LigandsIBA 06/2022 - 01/2019
2	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 06/2022 - 07/2018
2	APTIBA 03/2022 - 03/2019
2	LipopolysaccharidesIBA 01/2022 - 08/2015
2	Sulfhydryl Compounds (Thiols)IBA 01/2022 - 01/2022
2	NanovaccinesIBA 01/2022 - 03/2021
2	InterferonsIBA 01/2022 - 01/2021
2	HydrogelsIBA 01/2022 - 01/2019
2	DisulfidesIBA 01/2022 - 10/2017
2	RNA (Ribonucleic Acid)IBA 09/2021 - 06/2018
2	azobenzeneIBA 07/2021 - 07/2018
2	Bovine Serum AlbuminIBA 07/2021 - 01/2019
2	Cancer VaccinesIBA 03/2021 - 01/2020
2	Interleukin-12 (IL 12)IBA 01/2021 - 01/2019
2	cupric sulfide (CuS)IBA 01/2021 - 01/2015
2	Glutamine (L-Glutamine)FDA Link 01/2021 - 01/2020
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 01/2017
2	Fluorouracil (Carac)FDA LinkGeneric 01/2021 - 03/2014
2	Programmed Cell Death 1 ReceptorIBA 01/2021 - 01/2019
2	Hyaluronic Acid (Hyaluronan)IBA 08/2020 - 01/2020
2	CatalaseIBA 08/2020 - 07/2020

Therapy/Procedure

45	Therapeutics 06/2022 - 08/2014
22	Immunotherapy 03/2022 - 01/2016
19	Photothermal Therapy 06/2022 - 06/2014
17	Drug Therapy (Chemotherapy) 01/2021 - 01/2015
16	Lasers (Laser) 01/2022 - 01/2013
16	Precision Medicine 10/2021 - 06/2014
14	Photochemotherapy (Photodynamic Therapy) 01/2022 - 04/2015
6	Transplantation 01/2022 - 09/2015
4	Hepatectomy 01/2021 - 01/2014
2	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022 - 01/2019